Phase 3
Completed N=341
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
Arthritis, Psoriatic
Source: ClinicalTrials.gov NCT02294227 ↗
Enrolled (actual)
341
Serious AEs
13.4%
Results posted
Jul 2019
Primary outcomePrimary: Number of Participants With American College of Rheumatology 20 (ACR20) Response — 47; 45; 21 Participants — p=0.0002
◆ Published Evidence
Established
84citations · ~12 / year
Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study.
Summary
The purpose of this study was to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and maintenance dosing using pre-filled syringe (PFS) and to assess efficacy, safety and tolerability up to 2 years in subjects with active PsA despite current or previous NSAID or DMARD therapy
Linked Publications (3)
-
Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study.
-
Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis.
-
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With American College of Rheumatology 20 (ACR20) Response |
33; 26; 22 | — |
| SECONDARY Disease Activity Score (DAS-C28-CRP) Score Change From Baseline Using MMRM at Week 16 |
-0.98; -0.84; -0.21 | — |
| SECONDARY Psoriatic Area and Severity Index 75 (PASI75) |
29; 27; 5 | — |
| SECONDARY Short Form Health Survey Physical Component Score (SF-36-PCS) |
3.42; 3.44; 0.63 | — |
| SECONDARY Number of Participants With American College of Rheumatology 50 (ACR50) |
26; 19; 7 | — |
| SECONDARY Number of Participants With American College of Rheumatology 20 (ACR20) Response |
33; 26; 22 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of Psoriatic Arthritis (PsA) classified by ClASsification criteria for Psoriatic ARthritis (CASPAR) criteria.
- Rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies negative.
- Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis.
- Inadequate control of symptoms with NSAID.
- Other protocol-defined inclusion criteria do apply.
Exclusion Criteria
- Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing infectious or malignant process.
- Subjects taking high potency opioid analgesics.
- Previous exposure to secukinumab or other biologic drug directly targeting interleukin-17 (IL-17) or IL-17 receptor.
- Ongoing use of prohibited psoriasis treatments / medications.
- Subjects who have ever received biologic immunomodulating agents except for those targeting TNFα.
- Previous treatment with any cell-depleting therapies.
Data sourced from ClinicalTrials.gov (NCT02294227) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.